Liquidia (LQDA) Net Income towards Common Stockholders (2020 - 2026)
Liquidia's (LQDA) quarterly Net Income towards Common Stockholders came in at $52.9 million in Q1 2026, up 237.83% year-on-year from $15.7 million in Q1 2025, and up 263.33% quarter-over-quarter from $14.6 million in Q4 2025.
Liquidia (LQDA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Liquidia's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at $52.9 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 237.83% year-over-year to $52.9 million in Q1 2026; TTM through Mar 2026 was -$186.9 million, a 23.86% increase from a year earlier, with the FY2025 full-year figure at -$293.7 million, down 28.44% from the prior year.
- Net Income towards Common Stockholders grew to $52.9 million in Q1 2026 per LQDA's latest filing, from $14.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $52.9 million in Q1 2026 and bottomed at -$149.9 million in Q3 2025.
- The 5-year median for Net Income towards Common Stockholders is -$31.2 million (2023), against an average of -$43.9 million.
- Across the five-year window, Net Income towards Common Stockholders slumped 293.38% in 2024 and soared 237.83% in 2026, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$6.5 million in 2022, then sank by 229.66% to -$21.5 million in 2023, then slumped by 78.81% to -$38.5 million in 2024, then jumped by 137.8% to $14.6 million in 2025, then soared by 263.33% to $52.9 million in 2026.
- Per Business Quant, the three latest LQDA Net Income towards Common Stockholders figures stand at $52.9 million (Q1 2026), $14.6 million (Q4 2025), and -$149.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.91 Bn | 88.04 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.89 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Liquidia | 7.59 Bn | 7.36 Bn | 121.79 Mn | 52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.88 Mn |
| Dec 31, 2025 | 14.56 Mn |
| Sep 30, 2025 | -149.91 Mn |
| Jun 30, 2025 | -104.39 Mn |
| Mar 31, 2025 | -38.37 Mn |
| Dec 31, 2024 | -38.51 Mn |
| Sep 30, 2024 | -75.21 Mn |
| Jun 30, 2024 | -93.32 Mn |
| Mar 31, 2024 | -121.96 Mn |
| Dec 31, 2023 | -21.54 Mn |
| Sep 30, 2023 | -31.18 Mn |
| Jun 30, 2023 | -53.03 Mn |
| Mar 31, 2023 | -31.00 Mn |
| Dec 31, 2022 | -6.53 Mn |
| Sep 30, 2022 | -19.38 Mn |
| Jun 30, 2022 | -14.35 Mn |
| Mar 31, 2022 | -15.82 Mn |
| Dec 31, 2021 | -11.56 Mn |
| Sep 30, 2021 | -13.74 Mn |
| Jun 30, 2021 | -7.96 Mn |